Arcellx, Inc. (ACLX)
Company Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs.
It has strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.
Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 4, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 98 |
| CEO | Rami Elghandour |
Contact Details
Address: 25 West Watkins Mill Road, Suite A Gaithersburg, Maryland 20878 United States | |
| Phone | 240-723-6641 |
| Website | arcellx.com |
Stock Details
| Ticker Symbol | ACLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 0001786205 |
| CUSIP Number | 03940C100 |
| ISIN Number | US03940C1009 |
| Employer ID | 47-2855917 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Rami Elghandour | Chairman, Chief Executive Officer and Pres |
| Neeraj P. Teotia | Chief Commercial Officer |
| Dr. Christopher R. Heery M.D. | Chief Medical Officer |
| Michelle Lim Gilson | Chief Financial Officer |
| Michael Dombeck M.B.A. | Chief Operating Officer |
| Narinderjeet Singh M.S. | Chief Technical Officer |
| David Tice Ph.D. | Chief Scientific Officer |
| Myesha Lacy | Vice President of Investor Relations |
| Maryam Abdul-Kareem J.D., M.S. | General Counsel |
| Kate Aiken | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 28, 2023 | 144 | Filing |
| Dec 28, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 28, 2023 | 8-K | Current Report |
| Dec 18, 2023 | 144 | Filing |
| Dec 18, 2023 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Dec 14, 2023 | 144 | Filing |
| Dec 14, 2023 | 144 | Filing |
| Dec 12, 2023 | 8-K | Current Report |
| Dec 8, 2023 | 8-K | Current Report |
| Nov 15, 2023 | 8-K | Current Report |